Bayer to acquire KaNDy Therapeutics in $875M women’s health play
KaNDy's lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
KaNDy's lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
Longitude Capital leads round worth £25 million, which KaNDy will use to advance its non-hormonal menopause drug into Phase IIb clinical trial this year.